Researchers from the Center for Data Driven Discovery in Biomedicine (d3B) at Children’s Hospital of Philadelphia (CHOP) were among those from several collaborating institutions to identify potential therapeutic targets and prognostic markers for high-grade glioma, an aggressive form of brain cancer affecting children, adolescents and young adults. The findings were recently published in the journal Cell Reports Medicine.
Pediatric high-grade gliomas are some of the most chemotherapy-resistant and often surgically unresectable childhood cancers. Children affected by these aggressive brain tumors nearly always succumb to the disease within 10 months of their diagnoses.
Despite decades of clinical trials, there are no effective treatments for these patients, underscoring the need for new immunotherapies. Pediatric tumors are markedly different from those in adults, while adolescents and young adults remain understudied because their gliomas do not fit neatly into either pediatric or adult disease.
In this new study, which brought together collaborators associated with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), the Children’s Brain Tumor Network and the Philadelphia Coalition for a Cure, the researchers found that high-grade glioma varies by developmental stage and sex, with distinct tumor biology and outcomes.
The data could lead to more precise therapies and improved clinical trial design.
Read the press release from Icahn School of Medicine at Mount Sinai to learn more.
Featured in this article
Research
Researchers from the Center for Data Driven Discovery in Biomedicine (d3B) at Children’s Hospital of Philadelphia (CHOP) were among those from several collaborating institutions to identify potential therapeutic targets and prognostic markers for high-grade glioma, an aggressive form of brain cancer affecting children, adolescents and young adults. The findings were recently published in the journal Cell Reports Medicine.
Pediatric high-grade gliomas are some of the most chemotherapy-resistant and often surgically unresectable childhood cancers. Children affected by these aggressive brain tumors nearly always succumb to the disease within 10 months of their diagnoses.
Despite decades of clinical trials, there are no effective treatments for these patients, underscoring the need for new immunotherapies. Pediatric tumors are markedly different from those in adults, while adolescents and young adults remain understudied because their gliomas do not fit neatly into either pediatric or adult disease.
In this new study, which brought together collaborators associated with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), the Children’s Brain Tumor Network and the Philadelphia Coalition for a Cure, the researchers found that high-grade glioma varies by developmental stage and sex, with distinct tumor biology and outcomes.
The data could lead to more precise therapies and improved clinical trial design.
Read the press release from Icahn School of Medicine at Mount Sinai to learn more.
Contact us
Ben Leach